(Q50982765)

26 March 2018

title

Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria. (English)

1 reference

26 March 2018

1 reference

7

Charles R Scriver

0 references

Raymond C. Stevens

object named as

Raymond C Stevens

8

0 references

author name string

Alejandra Gámez

1

1 reference

26 March 2018

Lin Wang

2

1 reference

26 March 2018

Christineh N Sarkissian

3

1 reference

26 March 2018

Dan Wendt

4

1 reference

26 March 2018

Paul Fitzpatrick

5

1 reference

26 March 2018

Jeffrey F Lemontt

6

1 reference

26 March 2018

publication date

8 June 2007

1 reference

26 March 2018

Molecular Genetics and Metabolism

published in

1 reference

26 March 2018

volume

91

1 reference

26 March 2018

issue

4

1 reference

26 March 2018

page(s)

325-334

1 reference

26 March 2018

Structure-immunogenicity relationships of therapeutic proteins

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Minimizing the immunogenicity of protein therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Immunogenicity of engineered antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Potent antibody therapeutics by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Reduced antibody response to streptavidin through site-directed mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Rationally engineered proteins or antibodies with absent or reduced immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Phenylketonuria: old disease, new approach to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Study on a novel strategy to treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Crystal structure of phenylalanine ammonia lyase: multiple helix dipoles implicated in catalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Structural basis for the entrance into the phenylpropanoid metabolism catalyzed by phenylalanine ammonia-lyase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Crystal structure of histidine ammonia-lyase revealing a novel polypeptide modification as the catalytic electrophile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Prediction of sequential antigenic regions in proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Bioinformatics tools for identifying class I-restricted epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Effect of pegylation on pharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

Prediction of protein antigenic determinants from amino acid sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.015

10.1016/J.YMGME.2007.04.015

7 January 2021

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018